-- 加拿大帝国商业银行资本市场（CIBC Capital Markets）表示，在金价高企的背景下，包括Fuerte Metals (FMT.V)、Meridian Mining (MNO.TO) 和 Thesis Gold & Silver (TAU.V) 在内的黄金开发商的前景日益有利。 CIBC指出，金价上涨改善了项目的经济效益，而强劲的股权融资需求和创纪录的特许权使用费交易量继续支持项目推进，并增强了资产负债表的灵活性。 CIBC认为，近期黄金行业的整合有利于并购，因为它有助于缩小买卖双方预期之间的差距。 CIBC对黄金行业的覆盖范围更广，重点关注那些在经济效益、建设路径、管理团队能力和显著的估值重估潜力等方面最具吸引力的公司。 CIBC还将Skeena Resources (SKE.TO) 的目标股价从58加元上调至60加元。
Price: $9.51, Change: $+0.26, Percent Change: +2.81%
Aptiv (APTV) stock sell-off post Q1 results was unwarranted and likely driven by the lower-than-expected Q2 guide and rising cost pressures with 2026 more back-half weighted that appears like a steep ramp, UBS said in a Wednesday research report.While Q2 is impacted by "stranded cost" and Ford Motor (F) volume timing, H2 ramp looks more achievable than optics suggest amid positive developments in China and the non-auto segments, analysts wrote.The company expects positive growth from China in Q2, driven by new programs and normalization of production at key customer, the brokerage stated.Commodity headwinds should abate in H2 as recoveries lag, UBS said.The brokerage said it reiterated its buy rating on the stock and price target of $80 per share.Aptiv shares were up 4% in Wednesday trading.Price: $56.47, Change: $+1.64, Percent Change: +2.99%
Price: $15.79, Change: $-4.34, Percent Change: -21.55%
Ocular Therapeutix (OCUL) is moving closer to a potential US Food and Drug Administration filing for axpaxli, its long-acting treatment for wet age-related macular degeneration, as regulators begin formal discussions on a single-trial approval path, RBC Capital Markets said Tuesday in a report.Management said talks with the FDA are now ongoing, raising the possibility of submitting an application based on the company's successful pivotal study, rather than waiting for a second trial that is due to read out in early 2027, RBC said.The company plans to provide additional regulatory and program updates at an investor day on June 17, RBC said.Ocular continues to target a potential 2027 launch for axpaxli under a single-trial filing strategy, and RBC reiterated its view that the drug has a "positive benefit/risk profile."RBC maintained its rating of outperform, speculative risk, on Ocular stock with a $30 price target.Price: $9.84, Change: $+0.13, Percent Change: +1.29%